Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

NCT07691333 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

HR+/HER2- Breast Cancer
Breast Neoplasms

Interventions

DRUG: Kumorixilib 180mg
DRUG: Capecitabine 500mg
DRUG: Letrozole 2.5mg

Sponsor

Fujian Cancer Hospital